Friday, 26 May 2017

Specials News

  • Challenge No 3: Policy issues

    Specials |  Analysis | By Narayan Kulkarni | 0 Comment

    Government policies are among the major challenges before companies operating in the life sciences sector in the Asia Pacific region. For larger multinationals, policies favouring local com...Read more

  • India's 127-year-old ayurvedic leader clocks $847 mn

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    Growing on its legacy of 127 years, Dabur India clocked $847 million in 2012. The company is recognized for manufacturing traditional ayurvedic products that passes rigorous trials and au...Read more

  • What were the top 20 global M&A transactions of 2012?

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek out partners for mergers &am...Read more

  • BioSpectrum Technology Forum 2015 concludes successfully

    Specials |  News | By BioSpectrum Bureau | 0 Comment

    BioSpectrum Technology Forum 2015 was successfully concluded on August 14th, 2015 at The Taj Krishna, Hyderabad. Team BioSpectrum would like to express our heartfelt thanks to the Speakers ...Read more

  • Scotland woos Asian biotech firms

    Specials |  Analysis | By BioSpectrum Bureau | 0 Comment

    Life sciences has been chosen as one of the sectors that the autonomous Scottish government of Mr Alex Salmond is giving special attention to. Scotland is a small country of less than six m...Read more

  • Why did mergers & acquisitions plunge in APAC?

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    The global bioscience industry, in 2012, reported 450 mergers and acquisitions (M&A) transactions valued at $67 billion, which is about 10 percent lower than the number of deals struck ...Read more

  • Biotec's Dr Kirtikara: 70% of our staff is female

    Specials |  Influencers | By BioSpectrum Bureau | 0 Comment

    I graduated from Chulalongkorn University with a BS in Genetics, enrolled at the University of Connecticut, US, to continue studies in plant genetics, my area of interest. I obtained an MS ...Read more

  • TCM leader Yunnan Baiyao rides on R&D strength

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    Yunnan Baiyao Group is expanding its forte in the domain of traditional Chinese medicines and is concentrating on strengthening its R&D base. Recognized as a leading traditional Chine...Read more

  • VeriStem wins BioSpectrum award for stem cell technology

    Specials |  Influencers | By Amrita Tejasvi | 0 Comment

    Development of stem cell therapies requires innovative technologies and processes to overcome safety concerns and VeriStem Technologies of Singapore aims to fulfil this industry need. The c...Read more

  • AseaCyte predicts cell behaviour for future therapies

    Specials |  Influencers | By Amrita Tejasvi | 0 Comment

    Malaysia-based AseaCyte is emerging as an instrumental firm in the domain of human disease analysis, through its cell culture technology and cell-based analysis services. The start-up compa...Read more

  • Guangzhou records a whopping growth of over 50%

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    Clocking $1.3 billion revenue in 2012, Guangzhou Pharmaceutical recorded a growth of over 50 percent. A well-recognized name in China, Guangzhou Pharmaceutical Holdings is principally eng...Read more

  • What bioscience trends do the industry leaders predict for 2013?

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    The bioscience industry is about to step into 2013 and the year is predicted to unfold with new opportunities and trends that were so far just talk in the laboratories. First and foremost, ...Read more

  • What are the key mergers & acquisitions of Q1 2013?

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    Most pharmaceutical companies are sitting on the patent cliff and their drug pipelines are facing severe exhaustion. The big players of the industry are thus looking for mergers & acqui...Read more

  • What were the top 20 M&A deals in pharma and biotech sector in 2012?

    Specials |  Analysis | By Amrita Tejasvi | 0 Comment

    A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek out partners for mergers &am...Read more

  • Tackling TB in Asia

    Specials |  News | By BioSpectrum Bureau | 0 Comment

    Nearly three million new TB cases occur in South East Asia per year. Annually, about 700,000 women die of TB in Asia, and over three million contract the disease, accounting for about 17 mi...Read more

  • We have largest portfolio of new TB drugs'

    Specials |  News | By Saptarshi Chaudhuri | 0 Comment

    The Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization dedicated to the discovery and development of new, faster-acting and affordable tuberculosis medicines...Read more

  • How is India tackling the scourge of TB?

    Specials |  News | By Nandita Singh | 0 Comment

    The fact that one-fifth of the world's TB patients are in India (according to WHO) acts as a good catalyst for companies to set up their production units. Also, the vast pool of diseased su...Read more

  • Sandoz focuses on developing modern drugs for TB'

    Specials |  News | By Saptarshi Chaudhuri | 0 Comment

    Sandoz is the generic drug subsidiary of Novartis, a multinational pharmaceutical company. The company develops, manufactures and markets generic drugs as well as pharmaceutical and biotech...Read more

Survey Box

Will biobanking change healthcare in the world?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls